Glaucoma is not classified as a retinal disease. It is an optic neuropathy, meaning it is a disease of the optic nerve. The defining feature that separates glaucoma from other causes of vision loss is a characteristic pattern of damage to the optic nerve head, the spot at the back of your eye where nerve fibers exit toward the brain. That said, the relationship between glaucoma and the retina is closer than most people realize, which is why the question comes up so often.
Why Glaucoma Is an Optic Nerve Disease
The optic nerve carries visual information from your eye to your brain. In glaucoma, pressure inside the eye (or other factors) damages this nerve over time, causing progressive, irreversible vision loss. The American Academy of Ophthalmology defines primary open-angle glaucoma by its hallmark signs: cupping of the optic nerve, thinning of nerve fiber layers, and specific patterns of visual field loss. All of these point to the optic nerve as the primary target.
In a public health context, glaucoma is formally described as “an optic neuropathy associated with characteristic structural damage to the optic nerve and associated visual dysfunction.” It can be caused by various underlying processes, but what makes it glaucoma, rather than some other eye condition, is that specific pattern of optic nerve damage.
Where the Retina Fits In
The confusion is understandable because the retina plays a central role in how glaucoma develops and is detected. The cells that glaucoma kills are retinal ganglion cells, neurons that live in the innermost layer of the retina. These cells have long axons (nerve fibers) that travel across the retinal surface, converge at the optic nerve head, and bundle together to form the optic nerve itself. When glaucoma damages the optic nerve, those retinal ganglion cells die through a process called apoptosis, and the layer of nerve fibers on the retina thins.
So while the disease is defined by optic nerve damage, the destruction begins at the level of individual cells in the retina and is measurable there. Doctors use high-resolution imaging called optical coherence tomography (OCT) to measure the thickness of the retinal nerve fiber layer and a group of inner retinal layers collectively known as the ganglion cell complex. Thinning in these layers is one of the earliest detectable signs of glaucoma, sometimes appearing before a patient notices any vision changes.
How Glaucoma Differs From True Retinal Diseases
Retinal diseases target different structures and cause different patterns of vision loss. Age-related macular degeneration, for example, damages the macula, the central part of the retina responsible for sharp, detailed vision. Diabetic retinopathy involves leaking or abnormal blood vessels across the retina. Retinal detachment occurs when the retina physically separates from the tissue behind it.
These conditions typically reduce central vision first, making it harder to read, recognize faces, or see fine detail. Glaucoma works in the opposite direction. It characteristically attacks peripheral (side) vision in a silent, gradual way, which is why it can go unnoticed for years. Over time, untreated glaucoma narrows the visual field until central vision is eventually affected too. This peripheral-first pattern is a direct consequence of which nerve fibers are most vulnerable to damage at the optic nerve head.
Symptoms to Be Aware Of
Most forms of glaucoma produce no symptoms in their early stages. Open-angle glaucoma, the most common type, causes patchy blind spots in your side vision that develop so gradually you may not notice them. By the time central vision is affected, significant and permanent damage has already occurred. This is why glaucoma is sometimes called “the silent thief of sight.”
Acute angle-closure glaucoma is the exception. It causes sudden, severe symptoms: intense eye pain, headache, nausea, blurred vision, and halos around lights. This is a medical emergency requiring immediate treatment. Other variants like normal-tension glaucoma (where eye pressure stays in the normal range) and pigmentary glaucoma also tend to progress quietly, with blurred vision and peripheral vision loss developing over months or years.
Retinal diseases, by contrast, often announce themselves differently. A retinal detachment can cause sudden flashes of light, a shower of floaters, or a shadow creeping across your vision. Macular degeneration may cause straight lines to appear wavy. These symptom patterns are distinct from glaucoma’s slow peripheral fade.
How Glaucoma Is Diagnosed
Because glaucoma damages structures that overlap with the retina, the diagnostic process involves detailed retinal imaging. Eye doctors look for several key findings: cupping of the optic disc (the visible surface of the optic nerve head), thinning of the retinal nerve fiber layer around the disc, thinning of the ganglion cell layers in the macula, and characteristic visual field defects on perimetry testing.
OCT has become essential for early detection. It can measure the thickness of the three innermost retinal layers (which contain ganglion cell bodies, their axons, and their connections) with micrometer precision. Glaucoma preferentially thins these inner layers while leaving the deeper retinal layers intact. That’s a useful distinction: macular degeneration and diabetic retinopathy tend to affect the outer retinal layers and the blood vessel network, whereas glaucoma’s footprint is on the inner layers closest to the surface.
Treatment Targets the Nerve, Not the Retina
Current glaucoma treatment focuses almost entirely on lowering intraocular pressure, the only modifiable risk factor proven to slow progression. This is done through eye drops, laser procedures, or surgery, all aimed at either reducing fluid production inside the eye or improving its drainage. None of these treatments directly address the retinal ganglion cells that are dying.
That gap is a major area of interest in ophthalmology. Researchers are exploring neuroprotective strategies that would target the retinal ganglion cells themselves, attempting to keep them alive even when pressure or other insults threaten them. These approaches focus on the degenerative processes happening at the cellular level: disrupted energy metabolism, inflammation, interrupted transport of nutrients along nerve fibers, and the cell death pathways that ganglion cells activate under stress. No neuroprotective treatment has reached routine clinical use yet, but multiple clinical trials are underway.
The Scale of the Problem
Glaucoma is one of the leading causes of irreversible blindness worldwide. Global prevalence of open-angle glaucoma among adults 40 and older is about 2.8%, affecting roughly 80.5 million people as of 2024. That number is projected to rise to 186.6 million by 2060, driven by aging populations. East Asia is expected to see the steepest increase, with prevalence rising by about 50%.
Because the disease is silent in its early stages and vision loss cannot be reversed once it occurs, routine eye exams with optic nerve evaluation remain the most important tool for catching glaucoma before it causes significant damage. The retina is where doctors look for early clues, but the disease itself belongs to the optic nerve.